These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30887844)

  • 21. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
    Hanna DL; Loupakis F; Yang D; Cremolini C; Schirripa M; Li M; Matsusaka S; Berger MD; Miyamoto Y; Zhang W; Ning Y; Antoniotti C; Salvatore L; Moran M; Zeger G; Astrow SH; Falcone A; Lenz HJ
    Clin Colorectal Cancer; 2018 Sep; 17(3):e471-e488. PubMed ID: 29636300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study.
    Kotani D; Yoshino T; Kotaka M; Kawazoe A; Masuishi T; Taniguchi H; Yamazaki K; Yamanaka T; Oki E; Muro K; Komatsu Y; Bando H; Satake H; Kato T; Tsuji A
    Invest New Drugs; 2021 Dec; 39(6):1649-1655. PubMed ID: 34019214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28.
    Sunakawa Y; Fujita K; Ichikawa W; Ishida H; Yamashita K; Araki K; Miwa K; Kawara K; Akiyama Y; Yamamoto W; Nagashima F; Saji S; Sasaki Y
    Oncology; 2012; 82(4):242-8. PubMed ID: 22508373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOLFOXIRI plus Bevacizumab Versus FOLFOX plus Panitumumab for Metastatic Left-Sided RAS/BRAF Wild-Type Colorectal Cancer: Which "Side" Are You On?
    Yu IS; Loree JM
    Oncologist; 2021 Apr; 26(4):277-280. PubMed ID: 33539032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.
    Modest DP; Rivera F; Bachet JB; de Braud F; Pietrantonio F; Koukakis R; Demonty G; Douillard JY
    Int J Cancer; 2019 Jul; 145(2):576-585. PubMed ID: 30614531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.
    Cremolini C; Marmorino F; Loupakis F; Masi G; Antoniotti C; Salvatore L; Schirripa M; Boni L; Zagonel V; Lonardi S; Aprile G; Tamburini E; Ricci V; Ronzoni M; Pietrantonio F; Valsuani C; Tomasello G; Passardi A; Allegrini G; Di Donato S; Santini D; Falcone A;
    BMC Cancer; 2017 Jun; 17(1):408. PubMed ID: 28599628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
    Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
    Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab.
    Loupakis F; Schirripa M; Caparello C; Funel N; Pollina L; Vasile E; Cremolini C; Salvatore L; Morvillo M; Antoniotti C; Marmorino F; Masi G; Falcone A
    Br J Cancer; 2013 Jun; 108(12):2549-56. PubMed ID: 23703247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer.
    Sunakawa Y; Schirripa M; Lenz HJ
    Crit Rev Oncol Hematol; 2016 Apr; 100():117-26. PubMed ID: 26850575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Modified FOLFOXIRI+α in the Treatment of Advanced and Recurrent Colorectal Cancer: A Single-center Experience.
    Kobayashi K; Yamaguchi S; Ito S; Torashima Y; Inoue Y; Okada S; Enjoji T; Tetsuo H; Kuba S; Kosaka T; Adachi T; Hidaka M; Yamanouchi K; Kanetaka K; Takatsuki M; Eguchi S
    Intern Med; 2020 May; 59(10):1239-1245. PubMed ID: 32074573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.
    Tomasello G; Petrelli F; Ghidini M; Russo A; Passalacqua R; Barni S
    JAMA Oncol; 2017 Jul; 3(7):e170278. PubMed ID: 28542671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
    Fornaro L; Vasile E; Masi G; Loupakis F; Baldi GG; Allegrini G; Salvatore L; Cremolini C; Cupini S; Cortesi E; Tuzi A; Granetto C; Brunetti IM; Ricci S; Falcone A
    Clin Colorectal Cancer; 2012 Mar; 11(1):71-6. PubMed ID: 21903485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial.
    Aranda E; Viéitez JM; Gómez-España A; Gil Calle S; Salud-Salvia A; Graña B; Garcia-Alfonso P; Rivera F; Quintero-Aldana GA; Reina-Zoilo JJ; González-Flores E; Salgado Fernández M; Guillén-Ponce C; Garcia-Carbonero R; Safont MJ; La Casta Munoa A; García-Paredes B; López López R; Sastre J; Díaz-Rubio E;
    ESMO Open; 2020 Nov; 5(6):e000944. PubMed ID: 33148620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rate of Curative Surgery in Real-world Patients with Unresectable Metastatic Colorectal Cancer Treated with FOLFOXIRI ± Bevacizumab: A Western Canadian Province Experience.
    Bhatti T; Moser M; Tan KT; Chalchal H; Souied O; Le D; Shaw J; Zaidi A; Gill D; Ahmed S
    J Gastrointest Cancer; 2022 Jun; 53(2):427-433. PubMed ID: 33779898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New oxaliplatin-based combinations in the treatment of colorectal cancer.
    Cassidy J; Hochster H
    Colorectal Dis; 2003 Nov; 5 Suppl 3():1-9. PubMed ID: 23573555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy for metastatic colorectal cancer.
    Rosales J; Leong LA
    J Natl Compr Canc Netw; 2005 Jul; 3(4):525-9. PubMed ID: 16038643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of first-line systemic therapy in patients with metastatic colorectal cancer: a network meta-analysis of randomized controlled trials.
    Zhan Y; Cheng X; Mei P; Tan S; Feng W; Jiang H
    BMC Cancer; 2024 Jul; 24(1):893. PubMed ID: 39048944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
    Nipp RD; Ryan DP
    Oncologist; 2015 Mar; 20(3):236-8. PubMed ID: 25660156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
    Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M
    Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Chinese expert consensus on the clinical application of the Chinese modified triplet combination with irinotecan, oxaliplatin and continuous infusional 5-fluorouracil/leucovorin for colorectal cancer].
    Committee of Colorectal Cancer, Chinese Southern Oncology Group
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Jun; 24(6):473-479. PubMed ID: 34148311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.